Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Brooklyn Investment Group, the most common co-covered peer. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. I-Mab appears in 2 tracked Cross-Sector stories from August 22, 2026.
2 verified stories tracked
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Brooklyn Investment Group, the most common co-covered peer. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. I-Mab appears in 2 tracked Cross-Sector stories from August 22, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering I-Mab. Shared-story counts are live from our verified record — not editorial picks.
Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
